Trial
NCT03087448
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Novartis Pharmaceuticals; University of California, Davis
Condition
Non-small Cell Lung Cancer
Intervention
Ceritinib
Why stopped
Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-27